Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The safety profile of XOSPATA is based on 319 patients with relapsed or refractory AML treated with gilteritinib 120 mg daily in three clinical trials. The median duration of exposure to XOSPATA was 3.6 months (range 0.1 to 43.4 months).
Fatal adverse reactions occurred in 2% of patients receiving XOSPATA. These included cardiac arrest (1%) and one case each of differentiation syndrome and pancreatitis. The most frequent (≥5%) nonhematological serious adverse reactions reported in patients were fever (13%), dyspnea (9%), renal impairment (8%), transaminase increased (6%) and noninfectious diarrhea (5%).
Of the 319 patients, 91 (29%) required a dose interruption due to an adverse reaction; the most common adverse reactions leading to dose interruption were aspartate aminotransferase increased (6%), alanine aminotransferase increased (6%) and fever (4%). Twenty patients (6%) required a dose reduction due to an adverse reaction. Twenty-two (7%) discontinued XOSPATA treatment permanently due to an adverse reaction. The most common (>1%) adverse reactions leading to discontinuation were aspartate aminotransferase increased (2%) and alanine aminotransferase increased (2%).
Overall, for the 319 patients, the most frequent (≥10%) all-grade nonhematological adverse reactions reported in patients were transaminase increased (51%), myalgia/arthralgia (50%), fatigue/malaise (44%), fever (41%), mucositis (41%), edema (40%), rash (36%), noninfectious diarrhea (35%), dyspnea (35%), nausea (30%), cough (28%), constipation (28%), eye disorders (25%), headache (24%), dizziness (22%), hypotension (22%), vomiting (21%), renal impairment (21%), abdominal pain (18%), neuropathy (18%), insomnia (15%) and dysgeusia (11%). The most frequent (≥5%) grade ≥3 nonhematological adverse reactions reported in patients were transaminase increased (21%), dyspnea (12%), hypotension (7%), mucositis (7%), myalgia/arthralgia (7%), and fatigue/malaise (6%). Shifts to grades 3-4 nonhematologic laboratory abnormalities included phosphate decreased 42/309 (14%), alanine aminotransferase increased 41/317 (13%), sodium decreased 37/314 (12%), aspartate aminotransferase increased 33/317 (10%), calcium decreased 19/312 (6%), creatine kinase increased 20/317 (6%), triglycerides increased 18/310 (6%), creatinine increased 10/316 (3%), and alkaline phosphatase increased 5/317 (2%).
Adverse reactions reported in the first 30 days of therapy on the ADMIRAL Study [see Clinical Studies (14)] are shown in Tables 2 and 3, according to whether patients were preselected for high intensity or low intensity chemotherapy.
Table 2: Adverse Reactions Reported in ≥10% (Any Grade) or ≥5% (Grade 3-5) of Patients with Relapsed or Refractory AML in the Pre-selected High Intensity Chemotherapy Subgroup in the First 30 Days of the ADMIRAL Trial| Adverse Reaction | Any Grade n (%) | Grade ≥3 n (%) |
|---|
XOSPATA (120 mg daily) n=149 | Chemotherapy n=68 | XOSPATA (120 mg daily) n=149 | Chemotherapy n=68 |
|---|
Musculoskeletal and connective tissue disorders |
Myalgia/arthralgia
| 56 (38) | 20 (29) | 1 (1) | 3 (4) |
Investigations |
Transaminase increased
| 46 (31) | 11 (16) | 15 (10) | 5 (7) |
General disorders and administration site conditions |
Fatigue/malaise
| 36 (24) | 9 (13) | 1 (1) | 2 (3) |
Fever | 25 (17) | 21 (31) | 2 (1) | 4 (6) |
Edema
| 20 (13) | 13 (19) | 0 | 0 |
Gastrointestinal disorders |
Constipation | 29 (20) | 10 (15) | 0 | 0 |
Mucositis
| 18 (12) | 30 (44) | 0 | 5 (7) |
Nausea | 23 (15) | 26 (38) | 0 | 0 |
Abdominal pain
| 16 (11) | 16 (24) | 0 | 0 |
Blood and lymphatic system disorder |
Febrile neutropenia | 26 (17) | 30 (44) | 26 (17) | 30 (44) |
Skin and subcutaneous tissue disorders |
Rash
| 23 (15) | 21 (31) | 1 (1) | 2 (3) |
Respiratory, thoracic and mediastinal disorders |
Dyspnea
| 20 (13) | 9 (13) | 1 (1) | 6 (9) |
Cough | 18 (12) | 5 (7) | 1 (1) | 0 |
Nervous system disorders |
Neuropathy
| 19 (13) | 0 | 0 | 0 |
Dizziness
| 17 (11) | 2 (3) | 0 | 0 |
Headache | 17 (11) | 12 (18) | 0 | 0 |
Table 3: Adverse Reactions Reported in ≥10% (Any Grade) or ≥5% (Grade 3-5) of Patients with Relapsed or Refractory AML in the Pre-selected Low Intensity Chemotherapy Subgroup in the First 30 Days of the ADMIRAL Trial| Adverse Reaction | Any Grade n (%) | Grade ≥3 n (%) |
|---|
XOSPATA (120 mg daily) n=97 | Chemotherapy n=41 | XOSPATA (120 mg daily) n=97 | Chemotherapy n=41 |
|---|
Investigations |
Transaminase increased
| 35 (36) | 6 (15) | 9 (9) | 1 (2) |
Blood and lymphatic system disorder |
Febrile neutropenia | 26 (27) | 5 (12) | 25 (26) | 5 (12) |
Musculoskeletal and connective tissue disorders |
Myalgia/arthralgia
| 21 (22) | 7 (17) | 2 (2) | 0 |
General disorders and administration site conditions |
Fatigue/malaise
| 20 (21) | 9 (22) | 4 (4) | 1 (2) |
Edema
| 19 (20) | 5 (12) | 1 (1) | 0 |
Fever | 11 (11) | 7 (17) | 0 | 0 |
Gastrointestinal disorders |
Mucositis
| 19 (20) | 7 (17) | 1 (1) | 1 (2) |
Constipation | 13 (13) | 5 (12) | 1 (1) | 0 |
Diarrhea | 12 (12) | 2 (5) | 0 | 0 |
Nausea | 10 (10) | 7 (17) | 0 | 0 |
Respiratory, thoracic and mediastinal disorders |
Dyspnea
| 11 (11) | 2 (5) | 3 (3) | 2 (5) |
Skin and subcutaneous tissue disorders |
Rash
| 10 (10) | 2 (5) | 2 (2) | 0 |
Other clinically significant adverse reactions occurring in ≤10% of patients included: electrocardiogram QT prolonged (9%), hypersensitivity* (8%), pancreatitis* (5%), cardiac failure* (4%), pericardial effusion (4%), acute febrile neutrophilic dermatosis (3%), differentiation syndrome (3%), pericarditis/myocarditis* (2%), large intestine perforation (1%), and posterior reversible encephalopathy syndrome (1%).
*Grouped terms: cardiac failure (cardiac failure, cardiac failure congestive, cardiomegaly, cardiomyopathy, chronic left ventricular failure, and ejection fraction decreased), hypersensitivity (anaphylactic reaction, angioedema, dermatitis allergic, drug hypersensitivity, erythema multiforme, hypersensitivity, and urticaria), pancreatitis (amylase increased, lipase increased, pancreatitis, pancreatitis acute), pericarditis/myocarditis (myocarditis, pericardial hemorrhage, pericardial rub, and pericarditis).
Selected post-baseline laboratory values that were observed in patients with relapsed or refractory AML are shown in Table 4.
Table 4: Shifts to Grade 3-4 Laboratory Abnormalities in Patients with Relapsed or Refractory AML by Pre-selected High Intensity and Low Intensity Chemotherapy in the First 30 Days of the ADMIRAL Trial | Pre-selected High Intensity Chemotherapy Subgroup | Pre-selected Low Intensity Chemotherapy Subgroup |
|---|
XOSPATA (120 mg daily) | Chemotherapy | XOSPATA (120 mg daily) | Chemotherapy |
|---|
Alanine aminotransferase increased | 7/149 (5%) | 1/66 (2%) | 7/95 (7%) | 1/41 (2%) |
Alkaline phosphatase increased | 1/149 (1%) | 0 | 0 | 0 |
Aspartate aminotransferase increased | 8/149 (5%) | 2/65 (3%) | 5/95 (5%) | 0 |
Calcium decreased | 2/149 (1%) | 3/65 (5%) | 3/94 (3%) | 0 |
Creatine kinase increased | 1/149 (1%) | 0 | 1/95 (1%) | 0 |
Phosphatase decreased | 4/144 (3%) | 6/65 (9%) | 4/93 (4%) | 3/38 (8%) |
Sodium decreased | 7/148 (5%) | 5/65 (8%) | 6/93 (6%) | 2/41 (5%) |
Triglycerides increased | 1/146 (1%) | 0 | 2/94 (2%) | 0 |